Pegylated-interferon plus ribavirin treatment does not alter the prevalence of resistance-associated substitutions to direct-acting antivirals in HCV genotype 1a patients

Pegylated-interferon plus ribavirin treatment does not alter the prevalence of resistance-associated substitutions to direct-acting antivirals in HCV genotype 1a patients

Zhi-wei Chen,* Xi-chen Pang,* Zhao Li, Hong Ren, Peng Hu Department of Infectious Diseases, Institute for Viral Hepatitis, The Key Laboratory of Molecular Biology for Infectious Diseases, Chinese Ministry of Education, The Second Affiliated Hospital of Chongqing M...

Full description

Bibliographic Details
Main Authors: Chen Z, Pang X, Li Z, Ren H, Hu P
Format: Article
Language:English
Published: Dove Medical Press 2017-08-01
Series:Infection and Drug Resistance
Subjects:
pegylated-interferon
ribavirin
direct-acting antivirals
resistance associated substitutions
prevalence
Online Access:https://www.dovepress.com/pegylated-interferon-plus-ribavirin-treatment-does-not-alter-the-preva-peer-reviewed-article-IDR

Internet

https://www.dovepress.com/pegylated-interferon-plus-ribavirin-treatment-does-not-alter-the-preva-peer-reviewed-article-IDR

Similar Items